<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01326780</url>
  </required_header>
  <id_info>
    <org_study_id>CA-P-8023</org_study_id>
    <nct_id>NCT01326780</nct_id>
  </id_info>
  <brief_title>A Study of a New Drug Treatment for Acne</brief_title>
  <official_title>A Multi-Center, Double-Blind, Vehicle Controlled, Phase II Study of JNJ 10229570-AAA for the Treatment of Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch Health Americas, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch Health Americas, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to determine if three different doses of a new acne treatment are safe and better at
      reducing facial acne than a treatment without active ingredient.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 400 male and female subjects with moderate facial acne vulgaris will be
      enrolled in this randomized, multi-center study. Following satisfaction of entry criteria and
      screening procedures, subjects will be randomized to either 1.2%, 2.4%, or 3.6% facial cream
      (JNJ 10229570-AAA) or color-matched vehicle. Subjects will apply the study medication once
      daily on the face for 12 weeks. Safety will be monitored throughout the study duration.
      Efficacy will be assessed by facial lesion counts and by the investigator global evaluation
      of acne severity at Baseline and at Weeks 2, 4, 6, 8, 10, and 12. Approximately 50 subjects
      from one investigational site also will have serums collected at Weeks 6 and 12 for
      evaluation of the multiple dose pharmacokinetics of JNJ 10229570-AAA cream.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 31, 2011</start_date>
  <completion_date type="Actual">March 31, 2012</completion_date>
  <primary_completion_date type="Actual">March 31, 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Total Acne Lesion Counts</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Change in lesion counts between baseline and end of study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Non-inflammatory Acne Lesion Counts</measure>
    <time_frame>Baseline through Week 12</time_frame>
    <description>Change in sum of open and closed comedones.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Inflammatory Acne Lesion Counts</measure>
    <time_frame>Baseline through Week 12</time_frame>
    <description>Change in sum of papules and pustules</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in the Non-Inflammatory Acne Lesion Counts</measure>
    <time_frame>Baseline through Week 12</time_frame>
    <description>Percent Change in the Non-Inflammatory Acne Lesion Counts (the sum of open and closed comedones)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in the Inflammatory Acne Lesion Counts</measure>
    <time_frame>Baseline through Week 12</time_frame>
    <description>Percent Change in Inflammatory Acne Lesion Counts (sum of of papules and pustules)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Acne Lesion Counts</measure>
    <time_frame>Baseline through Week 12.</time_frame>
    <description>Percent change in Total Acne Lesion Counts (inflammatory lesions and non-inflammatory lesions)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">431</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>1.2% Facial Cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.2% JNJ 10229570-AAA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2.4% Facial Cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.4% JNJ 10229570-AAA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3.6% Facial Cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.6% JNJ 10229570-AAA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0% Facial Cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1.2% JNJ 10229570-AAA</intervention_name>
    <description>1.2% JNJ 10229570-AAA 1.2% cream applied once daily to the face for 12 weeks</description>
    <arm_group_label>1.2% Facial Cream</arm_group_label>
    <other_name>Not yet marketed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2.4% JNJ 10229570-AAA</intervention_name>
    <description>2.4% JNJ 10229570-AAA 2.4% cream applied once daily to the face for 12 weeks</description>
    <arm_group_label>2.4% Facial Cream</arm_group_label>
    <other_name>Not yet marketed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3.6% JNJ 10229570-AAA</intervention_name>
    <description>3.6% JNJ 10229570-AAA 3.6% cream applied once daily to the face for 12 weeks</description>
    <arm_group_label>3.6% Facial Cream</arm_group_label>
    <other_name>Not yet marketed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vehicle control</intervention_name>
    <description>Color matched cream vehicle, applied once daily to the face for 12 weeks</description>
    <arm_group_label>0% Facial Cream</arm_group_label>
    <other_name>Not marketed</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  12 years of age or older, with moderate facial acne vulgaris as defined in the
             protocol

          -  If female of childbearing potential, must take a pregnancy test and have a negative
             result

          -  Females of childbearing potential must also agree to use an adequate method of birth
             control, which would include:

               -  systemic birth control (Subjects must have been taking the same type of birth
                  control for at least 3 months prior to entering the study and must not change
                  type of birth control during the study)

               -  Condom with spermicide

               -  IUD. Females who have had a hysterectomy, bilateral oophorectomy or bilateral
                  tubal ligation are not required to use additional birth control methods

        Exclusion Criteria:

          -  Known sensitivity to any of the ingredients in the study medication

          -  More than 3 nodulocystic acne lesions

          -  Use of acne treatments, therapies or medications within protocol-specified timeframes

          -  Presence of other skin conditions, diseases, or medical conditions that (per protocol
             or in the opinion of the investigator) may require concurrent therapy, interfere with
             the evaluation of the study medication, or compromise subject safety

          -  Excessive facial hair that may interfere with application of the medication and/or
             evaluations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnson Varughese</last_name>
    <role>Study Director</role>
    <affiliation>Bausch Health Americas, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Trials, Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas J. Stephens &amp; Associates, Inc.</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80915</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Horizons Clinical Research Ctr., LLC</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Florida Dermatology</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hilltop Research</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gwinnett Clinical Research</name>
      <address>
        <city>Snellville</city>
        <state>Georgia</state>
        <zip>30078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Specialists Research, Inc</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Clinical Study Center</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TKL Research</name>
      <address>
        <city>Rochelle Park</city>
        <state>New Jersey</state>
        <zip>07662</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Dermatology Associates</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hilltop Research</name>
      <address>
        <city>Miamiville</city>
        <state>Ohio</state>
        <zip>45147</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yardley Dermatology Associates</name>
      <address>
        <city>Yardley</city>
        <state>Pennsylvania</state>
        <zip>19067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Across America</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reliance Clinical Testing Services</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm</url>
    <description>FDA's Drug Finder</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 30, 2011</study_first_submitted>
  <study_first_submitted_qc>March 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2011</study_first_posted>
  <results_first_submitted>May 22, 2017</results_first_submitted>
  <results_first_submitted_qc>November 16, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 11, 2018</results_first_posted>
  <last_update_submitted>October 2, 2019</last_update_submitted>
  <last_update_submitted_qc>October 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acne</keyword>
  <keyword>Irritation</keyword>
  <keyword>Safety</keyword>
  <keyword>Sebum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>18 investigational sites: First patient enrolled: 08 March 2011, Last patient completed: 02 March 2012</recruitment_details>
      <pre_assignment_details>male and female subjects with moderate facial acne vulgaris, who met the entry criteria, were randomized with equal allocation to either 1.2%, 2.4%, or 3.6% JNJ 10229570-AAA cream or color-matched vehicle</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>0% Facial Cream</title>
          <description>Vehicle control Vehicle control : Color matched cream vehicle, applied once daily to the face for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>1.2% Facial Cream</title>
          <description>1.2% JNJ 10229570-AAA 1.2% JNJ 10229570-AAA : 1.2% JNJ 10229570-AAA 1.2% cream applied once daily to the face for 12 weeks</description>
        </group>
        <group group_id="P3">
          <title>2.4% Facial Cream</title>
          <description>2.4% JNJ 10229570-AAA 2.4% JNJ 10229570-AAA : 2.4% JNJ 10229570-AAA 2.4% cream applied once daily to the face for 12 weeks</description>
        </group>
        <group group_id="P4">
          <title>3.6% Facial Cream</title>
          <description>3.6% JNJ 10229570-AAA 3.6% JNJ 10229570-AAA : 3.6% JNJ 10229570-AAA 3.6% cream applied once daily to the face for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="109"/>
                <participants group_id="P3" count="109"/>
                <participants group_id="P4" count="107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="100"/>
                <participants group_id="P3" count="103"/>
                <participants group_id="P4" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>0% Facial Cream</title>
          <description>Vehicle control Vehicle control : Color matched cream vehicle, applied once daily to the face for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>1.2% Facial Cream</title>
          <description>1.2% JNJ 10229570-AAA 1.2% JNJ 10229570-AAA : 1.2% JNJ 10229570-AAA 1.2% cream applied once daily to the face for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>2.4% Facial Cream</title>
          <description>2.4% JNJ 10229570-AAA 2.4% JNJ 10229570-AAA : 2.4% JNJ 10229570-AAA 2.4% cream applied once daily to the face for 12 weeks</description>
        </group>
        <group group_id="B4">
          <title>3.6% Facial Cream</title>
          <description>3.6% JNJ 10229570-AAA 3.6% JNJ 10229570-AAA : 3.6% JNJ 10229570-AAA 3.6% cream applied once daily to the face for 12 weeks</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="106"/>
            <count group_id="B2" value="109"/>
            <count group_id="B3" value="109"/>
            <count group_id="B4" value="107"/>
            <count group_id="B5" value="431"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.9" spread="7.6"/>
                    <measurement group_id="B2" value="17.3" spread="4"/>
                    <measurement group_id="B3" value="19.7" spread="7"/>
                    <measurement group_id="B4" value="17.9" spread="5.5"/>
                    <measurement group_id="B5" value="18.7" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B5" value="198"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="54"/>
                    <measurement group_id="B5" value="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="109"/>
                    <measurement group_id="B4" value="107"/>
                    <measurement group_id="B5" value="431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Total Acne Lesion Counts</title>
        <description>Change in lesion counts between baseline and end of study</description>
        <time_frame>Baseline to Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0% Facial Cream</title>
            <description>Vehicle control Vehicle control : Color matched cream vehicle, applied once daily to the face for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>1.2% Facial Cream</title>
            <description>1.2% JNJ 10229570-AAA 1.2% JNJ 10229570-AAA : 1.2% JNJ 10229570-AAA 1.2% cream applied once daily to the face for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>2.4% Facial Cream</title>
            <description>2.4% JNJ 10229570-AAA 2.4% JNJ 10229570-AAA : 2.4% JNJ 10229570-AAA 2.4% cream applied once daily to the face for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>3.6% Facial Cream</title>
            <description>3.6% JNJ 10229570-AAA 3.6% JNJ 10229570-AAA : 3.6% JNJ 10229570-AAA 3.6% cream applied once daily to the face for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Acne Lesion Counts</title>
          <description>Change in lesion counts between baseline and end of study</description>
          <units>Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="109"/>
                <count group_id="O4" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.0" spread="27.43"/>
                    <measurement group_id="O2" value="-25.2" spread="30.23"/>
                    <measurement group_id="O3" value="-29.4" spread="30.30"/>
                    <measurement group_id="O4" value="-33.1" spread="29.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Non-inflammatory Acne Lesion Counts</title>
        <description>Change in sum of open and closed comedones.</description>
        <time_frame>Baseline through Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0% Facial Cream</title>
            <description>Vehicle control Vehicle control : Color matched cream vehicle, applied once daily to the face for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>1.2% Facial Cream</title>
            <description>1.2% JNJ 10229570-AAA 1.2% JNJ 10229570-AAA : 1.2% JNJ 10229570-AAA 1.2% cream applied once daily to the face for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>2.4% Facial Cream</title>
            <description>2.4% JNJ 10229570-AAA 2.4% JNJ 10229570-AAA : 2.4% JNJ 10229570-AAA 2.4% cream applied once daily to the face for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>3.6% Facial Cream</title>
            <description>3.6% JNJ 10229570-AAA 3.6% JNJ 10229570-AAA : 3.6% JNJ 10229570-AAA 3.6% cream applied once daily to the face for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Non-inflammatory Acne Lesion Counts</title>
          <description>Change in sum of open and closed comedones.</description>
          <units>Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="109"/>
                <count group_id="O4" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.6" spread="20.3"/>
                    <measurement group_id="O2" value="-12.0" spread="21.2"/>
                    <measurement group_id="O3" value="-14.3" spread="20.9"/>
                    <measurement group_id="O4" value="-15.3" spread="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Inflammatory Acne Lesion Counts</title>
        <description>Change in sum of papules and pustules</description>
        <time_frame>Baseline through Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0% Facial Cream</title>
            <description>Vehicle control Vehicle control : Color matched cream vehicle, applied once daily to the face for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>1.2% Facial Cream</title>
            <description>1.2% JNJ 10229570-AAA 1.2% JNJ 10229570-AAA : 1.2% JNJ 10229570-AAA 1.2% cream applied once daily to the face for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>2.4% Facial Cream</title>
            <description>2.4% JNJ 10229570-AAA 2.4% JNJ 10229570-AAA : 2.4% JNJ 10229570-AAA 2.4% cream applied once daily to the face for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>3.6% Facial Cream</title>
            <description>3.6% JNJ 10229570-AAA 3.6% JNJ 10229570-AAA : 3.6% JNJ 10229570-AAA 3.6% cream applied once daily to the face for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Inflammatory Acne Lesion Counts</title>
          <description>Change in sum of papules and pustules</description>
          <units>Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="109"/>
                <count group_id="O4" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.4" spread="13.4"/>
                    <measurement group_id="O2" value="-13.2" spread="16.3"/>
                    <measurement group_id="O3" value="-15.1" spread="14.1"/>
                    <measurement group_id="O4" value="-18.1" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in the Non-Inflammatory Acne Lesion Counts</title>
        <description>Percent Change in the Non-Inflammatory Acne Lesion Counts (the sum of open and closed comedones)</description>
        <time_frame>Baseline through Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0% Facial Cream</title>
            <description>Vehicle control Vehicle control : Color matched cream vehicle, applied once daily to the face for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>1.2% Facial Cream</title>
            <description>1.2% JNJ 10229570-AAA 1.2% JNJ 10229570-AAA : 1.2% JNJ 10229570-AAA 1.2% cream applied once daily to the face for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>2.4% Facial Cream</title>
            <description>2.4% JNJ 10229570-AAA 2.4% JNJ 10229570-AAA : 2.4% JNJ 10229570-AAA 2.4% cream applied once daily to the face for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>3.6% Facial Cream</title>
            <description>3.6% JNJ 10229570-AAA 3.6% JNJ 10229570-AAA : 3.6% JNJ 10229570-AAA 3.6% cream applied once daily to the face for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in the Non-Inflammatory Acne Lesion Counts</title>
          <description>Percent Change in the Non-Inflammatory Acne Lesion Counts (the sum of open and closed comedones)</description>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="109"/>
                <count group_id="O4" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.6" spread="39.3"/>
                    <measurement group_id="O2" value="-21.7" spread="43.1"/>
                    <measurement group_id="O3" value="-31.2" spread="41.0"/>
                    <measurement group_id="O4" value="-30.8" spread="37.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in the Inflammatory Acne Lesion Counts</title>
        <description>Percent Change in Inflammatory Acne Lesion Counts (sum of of papules and pustules)</description>
        <time_frame>Baseline through Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0% Facial Cream</title>
            <description>Vehicle control Vehicle control : Color matched cream vehicle, applied once daily to the face for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>1.2% Facial Cream</title>
            <description>1.2% JNJ 10229570-AAA 1.2% JNJ 10229570-AAA : 1.2% JNJ 10229570-AAA 1.2% cream applied once daily to the face for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>2.4% Facial Cream</title>
            <description>2.4% JNJ 10229570-AAA 2.4% JNJ 10229570-AAA : 2.4% JNJ 10229570-AAA 2.4% cream applied once daily to the face for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>3.6% Facial Cream</title>
            <description>3.6% JNJ 10229570-AAA 3.6% JNJ 10229570-AAA : 3.6% JNJ 10229570-AAA 3.6% cream applied once daily to the face for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in the Inflammatory Acne Lesion Counts</title>
          <description>Percent Change in Inflammatory Acne Lesion Counts (sum of of papules and pustules)</description>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="109"/>
                <count group_id="O4" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.6" spread="36.3"/>
                    <measurement group_id="O2" value="-35.4" spread="45.3"/>
                    <measurement group_id="O3" value="-44.7" spread="41.1"/>
                    <measurement group_id="O4" value="-48.5" spread="31.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Acne Lesion Counts</title>
        <description>Percent change in Total Acne Lesion Counts (inflammatory lesions and non-inflammatory lesions)</description>
        <time_frame>Baseline through Week 12.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0% Facial Cream</title>
            <description>Vehicle control Vehicle control : Color matched cream vehicle, applied once daily to the face for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>1.2% Facial Cream</title>
            <description>1.2% JNJ 10229570-AAA 1.2% JNJ 10229570-AAA : 1.2% JNJ 10229570-AAA 1.2% cream applied once daily to the face for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>2.4% Facial Cream</title>
            <description>2.4% JNJ 10229570-AAA 2.4% JNJ 10229570-AAA : 2.4% JNJ 10229570-AAA 2.4% cream applied once daily to the face for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>3.6% Facial Cream</title>
            <description>3.6% JNJ 10229570-AAA 3.6% JNJ 10229570-AAA : 3.6% JNJ 10229570-AAA 3.6% cream applied once daily to the face for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Acne Lesion Counts</title>
          <description>Percent change in Total Acne Lesion Counts (inflammatory lesions and non-inflammatory lesions)</description>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="109"/>
                <count group_id="O4" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.9" spread="32.7"/>
                    <measurement group_id="O2" value="-27.8" spread="35.1"/>
                    <measurement group_id="O3" value="-36.5" spread="36.5"/>
                    <measurement group_id="O4" value="-37.7" spread="29.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through 12 weeks.</time_frame>
      <desc>Adverse events were monitored throughout the study period starting with the signing of the informed consent until completion of the last study-related procedure.</desc>
      <group_list>
        <group group_id="E1">
          <title>0% Facial Cream</title>
          <description>Vehicle control Vehicle control : Color matched cream vehicle, applied once daily to the face for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>1.2% Facial Cream</title>
          <description>1.2% JNJ 10229570-AAA 1.2% JNJ 10229570-AAA : 1.2% JNJ 10229570-AAA 1.2% cream applied once daily to the face for 12 weeks</description>
        </group>
        <group group_id="E3">
          <title>2.4% Facial Cream</title>
          <description>2.4% JNJ 10229570-AAA 2.4% JNJ 10229570-AAA : 2.4% JNJ 10229570-AAA 2.4% cream applied once daily to the face for 12 weeks</description>
        </group>
        <group group_id="E4">
          <title>3.6% Facial Cream</title>
          <description>3.6% JNJ 10229570-AAA 3.6% JNJ 10229570-AAA : 3.6% JNJ 10229570-AAA 3.6% cream applied once daily to the face for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application Site Pruritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Johnson Varughese</name_or_title>
      <organization>Valeant</organization>
      <phone>908 927-1162</phone>
      <email>johnson.varughese@bauschhealth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

